
AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type of Arthritis
The U.S. Food and Drug Administration on Tuesday approved AbbVie Inc.’s ABBV Rinvoq (upadacitinib), 15 mg, once daily, for giant cell arteritis (GCA). GCA is an inflammation of blood vessels, called arteries, in and around the scalp. Earlier in April, the …